Blocking CD40/CD40L signaling by monoclonal antibodies was shown to be beneficial in the treatment of arthritis and atherosclerosis by disrupting CD40 function, and CD40 has been a key immunotherapeutic target for over 20 years [81]. The gene discussed is CD40; the disease is Arthritis.